Legal & General Group Plc Sells 394,212 Shares of Cencora, Inc. (NYSE:COR)

Legal & General Group Plc lowered its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 22.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,373,669 shares of the company's stock after selling 394,212 shares during the period. Legal & General Group Plc owned approximately 0.71% of Cencora worth $308,636,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. JFS Wealth Advisors LLC grew its holdings in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora during the fourth quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the period. Kentucky Trust Co purchased a new position in shares of Cencora in the 4th quarter worth $33,000. Finally, WASHINGTON TRUST Co grew its position in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

Shares of COR traded down $0.79 during mid-day trading on Monday, hitting $283.54. 244,010 shares of the company's stock were exchanged, compared to its average volume of 1,504,399. The firm has a market capitalization of $54.98 billion, a P/E ratio of 40.33, a P/E/G ratio of 1.31 and a beta of 0.55. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The business's 50 day moving average is $260.27 and its two-hundred day moving average is $245.16. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.78%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio (DPR) is 31.29%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COR. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Bank of America upped their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $284.20.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,675 shares of company stock valued at $8,034,778. 10.80% of the stock is currently owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.